In the subset of advanced NSCLC patients harbouring high Programmed Death-Ligand 1 (PD-L1) with a tumour proportion score (TPS) ≥ 50%, pembrolizumab alone is an established first-line option based on the KEYNOTE-024 [1]. The gene discussed is CD274; the disease is neoplasm.